Unity Biotechnology CEO Anirvan Ghosh said: “The results also suggest that UBX1325 may provide greater vision gains than ...

today announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment.

Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...

UNITY Biotechnology (NASDAQ:UBX) stock fell 30% after the company's mid-stage trial for its diabetic macular edema treatment ...

announced today that its Phase 2b ASPIRE clinical trial has yielded positive topline results for UBX1325, a therapeutic candidate for the treatment of diabetic macular edema (DME). The trial ...

The Phase 2b PROGRESS study involves a substantial sample size of 496 patients, suggesting robust data collection and potential for meaningful results in the treatment of diabetic peripheral ...

Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR 200's ...